GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Quick Ratio

Actavia Life Sciences (Actavia Life Sciences) Quick Ratio : 0.02 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Actavia Life Sciences's quick ratio for the quarter that ended in Mar. 2024 was 0.02.

Actavia Life Sciences has a quick ratio of 0.02. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Actavia Life Sciences's Quick Ratio or its related term are showing as below:

RASP' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.05   Max: 6
Current: 0.02

During the past 11 years, Actavia Life Sciences's highest Quick Ratio was 6.00. The lowest was 0.01. And the median was 0.05.

RASP's Quick Ratio is ranked worse than
99.03% of 1546 companies
in the Biotechnology industry
Industry Median: 3.595 vs RASP: 0.02

Actavia Life Sciences Quick Ratio Historical Data

The historical data trend for Actavia Life Sciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Quick Ratio Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.02 0.05 0.05

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.05 0.01 0.02

Competitive Comparison of Actavia Life Sciences's Quick Ratio

For the Biotechnology subindustry, Actavia Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Quick Ratio falls into.



Actavia Life Sciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Actavia Life Sciences's Quick Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Quick Ratio (A: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.096-0)/2.052
=0.05

Actavia Life Sciences's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.049-0)/2.23
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actavia Life Sciences  (OTCPK:RASP) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Actavia Life Sciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines